Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study)

被引：11

作者：

Namikawa, Kenjiro ^{[1
]}

Ito, Takamichi ^{[2
]}

Yoshikawa, Shusuke ^{[3
]}

Yoshino, Koji ^{[4
,29
]}

Kiniwa, Yukiko ^{[5
]}

Ohe, Shuichi ^{[6
]}

Isei, Taiki ^{[6
]}

Takenouchi, Tatsuya ^{[7
]}

Kato, Hiroshi ^{[8
]}

Mizuhashi, Satoru ^{[9
]}

Fukushima, Satoshi ^{[9
]}

Yamamoto, Yosuke ^{[10
]}

Inozume, Takashi ^{[10
]}

Fujisawa, Yasuhiro ^{[11
,30
]}

Yamasaki, Osamu ^{[12
,31
]}

Nakamura, Yasuhiro ^{[13
]}

Asai, Jun ^{[14
]}

Maekawa, Takeo ^{[15
]}

Funakoshi, Takeru ^{[16
]}

Matsushita, Shigeto ^{[17
]}

Nakano, Eiji ^{[1
,18
]}

Oashi, Kohei ^{[19
]}

Kato, Junji ^{[20
]}

Uhara, Hisashi ^{[20
]}

Miyagawa, Takuya ^{[21
]}

Uchi, Hiroshi ^{[22
]}

Hatta, Naohito ^{[23
]}

Tsutsui, Keita ^{[24
]}

Maeda, Taku ^{[25
]}

Matsuya, Taisuke ^{[26
]}

Yanagisawa, Hiroto ^{[27
]}

Muto, Ikko ^{[28
]}

Okumura, Mao ^{[1
]}

Ogata, Dai ^{[1
]}

Yamazaki, Naoya ^{[1
]}

机构：

[1] Natl Canc Ctr, Dept Dermatol Oncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo, 1040045, Japan

[2] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Japan

[3] Shizuoka Canc Ctr, Dept Dermatol, Shizuoka, Japan

[4] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Dermatol Oncol, Tokyo, Japan

[5] Shinshu Univ, Dept Dermatol, Matsumoto, Japan

[6] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[7] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[8] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Nagoya, Japan

[9] Kumamoto Univ, Dept Dermatol & Plast Surg, Kumamoto, Japan

[10] Chiba Univ, Dept Dermatol, Chiba, Japan

[11] Univ Tsukuba, Dept Dermatol, Tsukuba, Japan

[12] Okayama Univ, Dept Dermatol, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan

[13] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[14] Kyoto Prefectural Univ Med, Dept Dermatol, Kyoto, Japan

[15] Jichi Med Univ Hosp, Dept Dermatol, Shimotsuke, Tochigi, Japan

[16] Keio Univ, Dept Dermatol, Tokyo, Japan

[17] Natl Hosp Org Kagoshima Med Ctr, Dept Dermatooncol Dermatol, Kagoshima, Japan

[18] Kobe Univ, Dept Dermatol, Kobe, Japan

[19] Saitama Canc Ctr, Dept Dermatol, Saitama, Japan

[20] Sapporo Med Univ, Dept Dermatol, Sapporo, Japan

[21] Univ Tokyo, Dept Dermatol, Tokyo, Japan

[22] Natl Hosp Org Kyushu Canc Ctr, Dept Dermatooncol, Fukuoka, Japan

[23] Toyama Prefectural Cent Hosp, Dept Dermatol, Toyama, Japan

[24] Fukuoka Univ, Dept Dermatol, Fukuoka, Japan

[25] Hokkaido Univ, Dept Plast & Reconstruct Surg, Sapporo, Japan

[26] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Japan

[27] Saitama Med Univ, Dept Dermatol, Saitama, Japan

[28] Kurume Univ, Dept Dermatol, Kurume, Japan

[29] Japanese Fdn Canc Res, Dept Dermatol Oncol, Canc Inst Hosp, Tokyo, Japan

[30] Ehime Univ, Dept Dermatol, Matsuyama, Ehime, Japan

[31] Shimane Univ, Dept Dermatol, Fac Med, Matsue, Shimane, Japan

来源：

CANCER MEDICINE | 2023年 / 12卷 / 17期

关键词：

Asian; BRAF; immune-checkpoint inhibitor; melanoma; targeted therapy; METASTATIC MELANOMA; EFFICACY; SAFETY; COMBINATION; BLOCKADE; CANCER; IMMUNOTHERAPY; DABRAFENIB; TRAMETINIB; NIVOLUMAB;

D O I：

10.1002/cam4.6438

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Anti-PD-1-based immunotherapy is considered a preferred first-line treatment for advanced BRAF V600-mutant melanoma. However, a recent international multi-center study suggested that the efficacy of immunotherapy is poorer in Asian patients in the non-acral cutaneous subtype. We hypothesized that the optimal first-line treatment for Asian patients may be different.Methods: We retrospectively collected data of Asian patients with advanced BRAF V600-mutant melanoma treated with first-line BRAF/MEK inhibitors (BRAF/MEKi), anti-PD-1 monotherapy (Anti-PD-1), and nivolumab plus ipilimumab (PD-1/CTLA-4) between 2016 and 2021 from 28 institutions in Japan.Results: We identified 336 patients treated with BRAF/MEKi (n = 236), Anti-PD-1 (n = 64) and PD-1/CTLA-4 (n = 36). The median follow-up duration was 19.9 months for all patients and 28.6 months for the 184 pa tients who were alive at their last follow-up. For patients treated with BRAF/MEKi, anti-PD-1, PD-1/CTLA-4, the median ages at baseline were 62, 62, and 53 years (p = 0.03); objective response rates were 69%, 27%, and 28% (p < 0.001); median progression-free survival (PFS) was 14.7, 5.4, and 5.8 months (p = 0.003), and median overall survival (OS) was 34.6, 37.0 months, and not reached, respectively (p = 0.535). In multivariable analysis, hazard ratios (HRs) for PFS of Anti-PD-1 and PD-1/CTLA-4 compared with BRAF/MEKi were 2.30 (p < 0.001) and 1.38 (p = 0.147), and for OS, HRs were 1.37 (p = 0.111) and 0.56 (p = 0.075), respectively. In propensity-score matching, BRAF/MEKi showed a tendency for longer PFS and equivalent OS with PD-1/CTLA-4 (HRs for PD-1/CTLA-4 were 1.78 [p = 0.149]) and 1.03 [p = 0.953], respectively). For patients who received second-line treatment, BRAF/MEKi followed by PD-1/CTLA-4 showed poor survival outcomes.Conclusions: The superiority of PD-1/CTLA-4 over BRAF/MEKi appears modest in Asian patients. First-line BRAF/MEKi remains feasible, but it is difficult to salvage at progression. Ethnicity should be considered when selecting systemic therapies until personalized biomarkers are available in daily practice. Further studies are needed to establish the optimal treatment sequence for Asian patients.

引用

页码：17967 / 17980

页数：14

共 44 条

[1] Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?
Ascierto, Paolo A.
McArthur, Grant A.
[J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
[2] Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Ascierto, Paolo A. A.
Mandala, Mario
Ferrucci, Pier Francesso
Guidoboni, Massimo
Rutkowski, Piotr
Ferraresi, Virginia
Arance, Ana
Guida, Michele
Maiello, Evaristo
Gogas, Helen
Richtig, Erika
Fierro, Maria Teresa
Lebbe, Celeste
Helgadottir, Hildur
Queirolo, Paola
Spagnolo, Francesco
Tucci, Marco
Del Vecchio, Michele
Gonzales Cao, Maria
Minisini, Alessandro Marco
De Placido, Sabino
Sanmamed, Miguel F. F.
Mallardo, Domenico
Curvietto, Marcello
Melero, Ignacio
Palmieri, Giuseppe
Grimaldi, Antonio M.
Giannarelli, Diana
Dummer, Reinhard
Sileni, Vanna Chiarion
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 212 - +
[3] Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
Atkins, Michael B.
Lee, Sandra J.
Chmielowski, Bartosz
Tarhini, Ahmad A.
Cohen, Gary I.
Truong, Thach-Giao
Moon, Helen H.
Davar, Diwakar
O'Rourke, Mark
Stephenson, Joseph J.
Curti, Brendan D.
Urba, Walter J.
Brell, Joanna M.
Funchain, Pauline
Kendra, Kari L.
Ikeguchi, Alexandra P.
Jaslowski, Anthony
Bane, Charles L.
Taylor, Mark A.
Bajaj, Madhuri
Conry, Robert M.
Ellis, Robert J.
Logan, Theodore F.
Laudi, Noel
Sosman, Jeffrey A.
Crockett, David G.
Pecora, Andrew L.
Okazaki, Ian J.
Reganti, Sowjanya
Chandra, Sunandana
Guild, Samantha
Chen, Helen X.
Streicher, Howard Z.
Wolchok, Jedd D.
Ribas, Antoni
Kirkwood, John M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 186 - +
[4] Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy
Atkins, Michael B.
Julian, Cristina
Secrest, Matthew H.
Lee, Janet
Abajo-Guijarro, Ana M.
McKenna, Edward
[J]. FUTURE ONCOLOGY, 2022, 18 (18) : 2233 - 2245
[5] Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
Bai, X.
Flaherty, K. T.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 253 - 262
[6] Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Bai, Xue
Shoushtari, Alexander N.
Warner, Allison Betof
Si, Lu
Tang, Bixia
Cui, Chuanliang
Yang, Xiaoling
Wei, Xiaoting
Quach, Henry T.
Cann, Christopher G.
Zhang, Michael Z.
Pallan, Lalit
Harvey, Catriona
Kim, Michelle S.
Kasumova, Gyulnara
Sharova, Tatyana
Cohen, Justine, V
Lawrence, Donald P.
Freedman, Christine
Fadden, Riley M.
Rubin, Krista M.
Frederick, Dennie T.
Flaherty, Keith T.
Long, Georgina, V
Menzies, Alexander M.
Sullivan, Ryan J.
Boland, Genevieve M.
Johnson, Douglas B.
Guo, Jun
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : 401 - 410
[7] Effectiveness and safety of dabrafenib and trametinib in patients with BRAFV600 mutated metastatic melanoma in the real-world setting: Final results of the non-interventional COMBI-r study
Berking, C.
Livingstone, E.
Weichenthal, M.
Leiter-Stoppke, U.
Remy, J.
Eigentler, T.
Mohr, P.
Kiecker, F.
Loquai, C.
Debus, D.
Gutzmer, R.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S927 - S927
[8] Melanoma: Does Sequencing Really Matter?
Chandra, Sunandana
Choi, Jacob S. S.
Sosman, Jeffrey A. A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 167 - +
[9] Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, Diego
Morris, Luc G. T.
Grigg, Claud M.
Weber, Jeffrey K.
Samstein, Robert M.
Makarov, Vladimir
Kuo, Fengshen
Kendall, Sviatoslav M.
Requena, David
Riaz, Nadeem
Greenbaum, Benjamin
Carroll, James
Garon, Edward
Hyman, David M.
Zehir, Ahmet
Solit, David
Berger, Michael
Zhou, Ruhong
Rizvi, Naiyer A.
Chan, Timothy A.
[J]. SCIENCE, 2018, 359 (6375) : 582 - +
[10] The multiple roles of LDH in cancer
Claps, Giuseppina
Faouzi, Sara
Quidville, Virginie
Chehade, Feras
Shen, Shensi
Vagner, Stephan
Robert, Caroline
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (12) : 749 - 762

← 1 2 3 4 5 →